Denali Therapeutics CEO and leadership

Alex Schuth is Chief Operating Officer of Denali Therapeutics. He is a co-founder of the company and responsible for portfolio management, corporate development, and the legal group.

Since 2015, Alex and his team have helped build and advance a broad portfolio of therapeutic drug candidates from discovery stage to clinical development and established over 30 collaborations with partners in academia and industry to accelerate the discovery and development of medicines for neurodegenerative diseases.

Alex previously held various operational and leadership positions during a 10-year tenure at Genentech, including Head of Neuroscience Partnering, and contributed to the growth and success of Genentech’s pipeline across several therapeutic areas. Before joining Genentech, Alex worked in Merrill Lynch’s investment banking group in London, where his responsibilities included executing equity capital market transactions.

Alex holds an M.D. degree from the Charite Medical School at the Humboldt University in Berlin, Germany, and an M.B.A. from the Wharton School of the University of Pennsylvania.

Carole Ho is Chief Medical Officer and Head of Development. At Denali, Carole has built an integrated Development organization that is responsible for advancing therapeutic candidates from pre-IND enabling studies through Phase 1 to Phase 3 clinical trials. Under Carole’s leadership, her team has delivered on Denali’s biomarker driven development strategy to enable early target and pathway engagement in the clinic for therapeutics in development for Parkinson’s disease, Alzheimer's disease, and ALS.

Carole previously served as Vice President of Genentech Early Clinical Development and was responsible for delivery of pivotal trial-ready drug candidates in Neurology, Ophthalmology, Immunology, and Infectious Disease. During her 8-year tenure at Genentech, Carole held roles with leadership responsibility across multiple early- and late-stage clinical programs including Rituxan® for Wegener’s granulomatosis and microscopic polyangiitis, ocrelizumab for Multiple Sclerosis, lampalizumab for dry AMD, and crenezumab for Alzheimer’s Disease. At Genentech, in collaboration with Banner Health, Carole's team led the initiation of the world's first prevention trial in Alzheimer's disease in participants at risk for dementia due to a genetic mutation.

Carole completed her residency in Neurology at Harvard Medical School at the Massachusetts General Hospital / Brigham and Women’s Hospital, where she also served as Chief Resident. She obtained her M.D. from Cornell University and S.B. in Biochemical Sciences from Harvard College. Prior to her Industry career, Carole was on Faculty in the Department of Neurology at Stanford University. Carole currently serves on the Board of Directors of Beam Therapeutics.

Cindy Dunkle serves as Chief People Officer at Denali. In this position, she oversees all aspects of Human Resources and Environmental Health and Safety.

Cindy has been instrumental in the successful growth of the company, positioning science and leadership as a focus in attracting top talent. She drives HR strategy and value creation, fosters a culture of learning and innovation to enable each individual achieve their unique potential. Cindy has 25 years of experience with an emphasis in compensation, organizational development and talent acquisition.

Prior to Denali, Cindy held roles of increasing responsibility across corporate staffing and development functions at Avalanche Biotechnologies and Genentech. Cindy obtained a B.S. from Metropolitan State University.

Alex Schuth is Chief Operating Officer of Denali Therapeutics. He is a co-founder of the company and responsible for portfolio management, corporate development, and the legal group.

Since 2015, Alex and his team have helped build and advance a broad portfolio of therapeutic drug candidates from discovery stage to clinical development and established over 30 collaborations with partners in academia and industry to accelerate the discovery and development of medicines for neurodegenerative diseases.

Alex previously held various operational and leadership positions during a 10-year tenure at Genentech, including Head of Neuroscience Partnering, and contributed to the growth and success of Genentech’s pipeline across several therapeutic areas. Before joining Genentech, Alex worked in Merrill Lynch’s investment banking group in London, where his responsibilities included executing equity capital market transactions.

Alex holds an M.D. degree from the Charite Medical School at the Humboldt University in Berlin, Germany, and an M.B.A. from the Wharton School of the University of Pennsylvania.